India · Delayed Price · Currency is INR CORONA Remedies Statistics
Total Valuation
CORONA Remedies has a market cap or net worth of INR 112.94 billion. The enterprise value is 114.15 billion.
| Market Cap | 112.94B |
| Enterprise Value | 114.15B |
Important Dates
The next confirmed earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 61.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 69.00% |
| Owned by Institutions (%) | 6.11% |
| Float | 10.76M |
Valuation Ratios
The trailing PE ratio is 61.01 and the forward PE ratio is 45.17.
| PE Ratio | 61.01 |
| Forward PE | 45.17 |
| PS Ratio | 8.05 |
| PB Ratio | 15.12 |
| P/TBV Ratio | 23.33 |
| P/FCF Ratio | 204.09 |
| P/OCF Ratio | 49.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 38.87, with an EV/FCF ratio of 206.27.
| EV / Earnings | 61.66 |
| EV / Sales | 8.14 |
| EV / EBITDA | 38.87 |
| EV / EBIT | 44.62 |
| EV / FCF | 206.27 |
Financial Position
The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.22.
| Current Ratio | 0.96 |
| Quick Ratio | 0.53 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 2.98 |
| Interest Coverage | 36.67 |
Financial Efficiency
Return on equity (ROE) is 27.36% and return on invested capital (ROIC) is 25.62%.
| Return on Equity (ROE) | 27.36% |
| Return on Assets (ROA) | 14.96% |
| Return on Invested Capital (ROIC) | 25.62% |
| Return on Capital Employed (ROCE) | 30.28% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.12M |
| Profits Per Employee | 411,378 |
| Employee Count | 4,500 |
| Asset Turnover | 1.31 |
| Inventory Turnover | 2.05 |
Taxes
In the past 12 months, CORONA Remedies has paid 553.00 million in taxes.
| Income Tax | 553.00M |
| Effective Tax Rate | 23.00% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1,698.80 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 67.62 |
| Average Volume (20 Days) | 9,214 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CORONA Remedies had revenue of INR 14.03 billion and earned 1.85 billion in profits. Earnings per share was 30.27.
| Revenue | 14.03B |
| Gross Profit | 11.42B |
| Operating Income | 2.56B |
| Pretax Income | 2.40B |
| Net Income | 1.85B |
| EBITDA | 2.93B |
| EBIT | 2.56B |
| Earnings Per Share (EPS) | 30.27 |
Balance Sheet
The company has 441.20 million in cash and 1.65 billion in debt, with a net cash position of -1.21 billion.
| Cash & Cash Equivalents | 441.20M |
| Total Debt | 1.65B |
| Net Cash | -1.21B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 7.47B |
| Book Value Per Share | 122.09 |
| Working Capital | -128.60M |
Cash Flow
In the last 12 months, operating cash flow was 2.29 billion and capital expenditures -1.74 billion, giving a free cash flow of 553.40 million.
| Operating Cash Flow | 2.29B |
| Capital Expenditures | -1.74B |
| Depreciation & Amortization | 378.70M |
| Net Borrowing | 773.80M |
| Free Cash Flow | 553.40M |
| FCF Per Share | n/a |
Margins
Gross margin is 81.40%, with operating and profit margins of 18.21% and 13.19%.
| Gross Margin | 81.40% |
| Operating Margin | 18.21% |
| Pretax Margin | 17.13% |
| Profit Margin | 13.19% |
| EBITDA Margin | 20.91% |
| EBIT Margin | 18.21% |
| FCF Margin | 3.94% |
Dividends & Yields
CORONA Remedies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 24.15% |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.01% |
| Earnings Yield | 1.64% |
| FCF Yield | 0.49% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for CORONA Remedies is 1,929.00, which is 3.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1,929.00 |
| Price Target Difference | 3.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 16.21% |
| EPS Growth Forecast (3Y) | 25.90% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |